Novel therapies for lung cancer

Tien Hoang, Anne M. Traynor, Joan H. Schiller

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Lung cancer remains the leading cause of cancer mortality in the US. For the majority of patients with advanced non-small cell lung cancer, chemotherapy with or without radiation therapy is the mainstay of treatment. Despite the modest improvement in survival for these patients, prognosis remains dismal. However, the expanding knowledge of tumor biology in recent years has resulted in the promising development of a new class of "molecularly targeted" agents, which selectively target cancer cells at the molecular, biochemical, and genetic level, thus minimizing toxic effects on normal tissues. A wide range of molecularly targeted agents are being actively investigated in lung cancer therapy as single agents or in combination with conventional modalities. In this review, we discuss some of the agents furthest along in development: epidermal growth factor receptor inhibitors, anti-angiogenic agents, inhibitors of biologically important enzymes such as matrix metalloproteinases and farnesyltransferase, gene therapy including gene replacement and antisense therapy, and cell cycle disruptors.

Original languageEnglish (US)
Pages (from-to)229-241
Number of pages13
JournalSurgical Oncology
Issue number4
StatePublished - Dec 2002


  • Anti-angiogenesis
  • Epidermal growth factor receptors
  • Intracellular signaling transduction
  • Molecularly targeted agents
  • Vascular endothelial growth factors

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Novel therapies for lung cancer'. Together they form a unique fingerprint.

Cite this